Verisante Technology, Inc. Expands Intellectual Property Portfolio
March 12, 2014
VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Chinese Patent Office has issued a decision to grant Patent Application No. 2006800074 entitled “Methods and Apparatus for Measuring Cancerous Changes from Reflectance Spectral Measurements Obtained During Endoscopy Imaging”.
Verisante anticipates this patent will be applicable to the use of the Company’s Core™ devices for endoscopic applications in cancer detection and will further enhance Verisante’s intellectual property position, as the data analysis techniques can be adapted to many medical applications.
In addition to the abovementioned patent, the Company’s current intellectual property portfolio is comprised of:
- 2 international PCT applications and has exclusively licensed 3 US patents;
- 4 US patent applications;
- 3 Canadian patent applications;
- 3 Chinese patent applications;
- 3 European patent applications;
- 3 Israeli patent applications;
- 3 Indian patent applications;
- 3 Japanese patent applications;
- 2 Australian patent applications;
- 2 Russian patent applications;
- 2 Brazilian patent applications; and
- 1 international PCT patent application.
Patents Solely-held by Verisante
- 5 US patents;
- 1 Japanese patent;
- 1 regional European patent that resulted in 8 national patents one in each of Germany, UK, France, Netherland, Italy, Spain, Switzerland and Sweden;
- 1 Canadian patent application;
- 1 Chinese patent application; and
- 1 Japanese patent application.
“With numerous global patents already issued, and with numerous additional international patents pending, this new Chinese patent expands Verisante’s already formidable intellectual property estate,” said Thomas Braun, President & CEO. “As awareness and acceptance of our ground-breaking cancer detection technology platform continues to grow amongst physicians, patients and payors in global markets, it is important this opportunity is well protected.”
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, was awarded a 2013 Prism Award for Innovation in Photonics, as well as an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.